Description of Business |
9 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||
| Description of Business [Abstract] | ||||||||||||||||
| DESCRIPTION OF BUSINESS | NOTE 1 — DESCRIPTION OF BUSINESS
Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) is incorporated in Delaware as a C-Corporation. On December 1, 2025, the Company completed a merger with MindWave Innovations Inc. (“MindWave”), making MindWave a wholly owned subsidiary. Through this merger, the Company acquired digital assets including Bitcoin (“BTC”), Tether (“USDT”), and MindWaveDAO NILA tokens (“NILA Tokens”), along with operations related to digital asset activities. Until July 14, 2026, the Company also conducted a development-stage biopharmaceutical business, a purified honeybee venom-based drug for treating acute pain and inflammation from knee osteoarthritis (the “BioBusiness”), through its subsidiary Lokahi Therapeutics Inc. (“Lokahi”). As described below and in Note 3, the Company disposed of Lokahi during the three months ended September 30, 2026, and the BioBusiness is presented as a discontinued operation for all periods presented.
MindWave and its subsidiaries hold and transact in digital assets and constitute the Company’s Digital Asset segment. The acquisition was accounted for as an asset acquisition under ASC 805-50 because substantially all of the fair value of the gross assets acquired was concentrated in a group of similar identifiable assets and the acquired set did not constitute a business. The Company was the accounting acquirer. Consideration consisted of 747,702 shares of Series A Convertible Preferred Stock (as adjusted for the reverse stock split) with a fair value of $145,335,708, which was allocated to the identifiable assets acquired and liabilities assumed, principally digital assets, on a relative fair value basis; goodwill was recognized. The BioBusiness is presented as a discontinued operation; accordingly, continuing operations for the comparative 2025 periods consist of corporate activities only.
Until July 14, 2026, the Company operated its biopharmaceutical business through Lokahi. As of September 30, 2026, the corporate structure includes:
On April 24, 2026, the Company, MindWave and Lokahi entered into a Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) with Inscobee Inc. (now FreeT Inc.) and Apimeds Inc. (Korea), together with a related side letter, which provided for the separation of the BioBusiness. Under the Settlement Agreement, the Company agreed to transfer 51% of the outstanding equity of Lokahi to Lokahi’s designee following Lokahi’s payment of a $4,000,000 working capital contribution, and Lokahi assumed the Company’s notes payable — related party of $500,100. Of the $4,000,000 working capital contribution, $3,750,000 had been paid by Lokahi to MindWave as of June 30, 2026, comprising $3,000,000 funded into an escrow account maintained in an attorney trust account and $750,000 satisfied through Lokahi’s forgiveness of an advance previously made by Lokahi to MindWave on or about February 2, 2026; the remaining $250,000 had not been funded as of June 30, 2026. These amounts were intercompany and were eliminated in consolidation. RXRR Capital Partners paid no separate consideration for the 51% interest, which was transferred in exchange for Lokahi’s performance of its obligations under the Settlement Agreement, including the working capital contribution and the assumption of the notes payable — related party. In an acknowledgement dated July 14, 2026, the Company and Lokahi confirmed that Lokahi had completed the required actions and that the 51% interest had been transferred to RXRR Capital Partners, as Lokahi’s designee, with all rights to hold and vote the shares. The Company held a majority of the voting interest in Lokahi, and Lokahi remained a consolidated subsidiary, until July 14, 2026. The Company retained the remaining 49% interest in Lokahi until the merger described below.
On July 14, 2026, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack”) merged into Lokahi, with Lokahi surviving as a wholly owned subsidiary of Glucotrack. In the merger the Company’s remaining 49% interest in Lokahi was exchanged for 37,884 shares of Glucotrack common stock and the right to receive 22,691 shares of Glucotrack Series A preferred stock, each convertible into 100 shares of Glucotrack common stock, in each case before Glucotrack’s 1-for-15 reverse stock split effective August 31, 2026. Following the merger the Company no longer controls Lokahi and has deconsolidated it. The Company elected to measure the deconsolidation using Lokahi’s June 30, 2026 balances; Lokahi’s activity from July 1 through July 14, 2026 is not included in these condensed consolidated financial statements as they were nominal. The disposal of Lokahi represents a strategic shift that has a major effect on the Company’s operations and financial results, and the BioBusiness is presented as a discontinued operation for all periods presented. On September 10, 2026, the parties to the Settlement Agreement entered into a First Amendment that amends its provisions on the composition of the Company’s board of directors. See Note 3 and Note 5.
On August 19, 2026, the Company entered into an Assignment and Transfer Agreement of Certain Apitox Rights with FreeT Inc. (“FreeT”), formerly Inscobee Inc., under which FreeT assigned to the Company 100% of the Apitox market for Korean medicine clinics in Korea, a 25% royalty on U.S. commercialization proceeds, a 25% participation in net proceeds from overseas rights agreements, quarterly information rights and certain ancillary rights. The assignment excludes ownership of the underlying Apitox intellectual property, and the Company assumed no liabilities of FreeT. The agreement states that it is entered into as part of the parties’ broader strategic relationship and specifies no monetary consideration; any additional consideration would be set out in a separate written agreement, and none has been executed. The rights were recorded at a carrying amount of $nil. FreeT is a related party (see Note 11). The Company does not conduct development of Apitox, which is conducted by Lokahi as a subsidiary of Glucotrack.
Following the disposal of Lokahi, the Company’s continuing operations consist of its Digital Asset segment and corporate activities. MindWave operates as a blockchain and digital asset technology business and has been generating realized gains, trading gains, and digital asset yield income. In addition to holding, sale and conversion of digital assets, MindWave is developing commercial blockchain and technology applications, including initiatives intended to establish recurring revenue opportunities and expand its U.S. commercial presence. In September 2026, MindWave entered into technology services agreements with AQUAE Holdings Pte. Ltd. and Flash Sports & Media Holdings, Inc.
The Company’s digital asset activities are limited to the holding, sale and conversion of tokens acquired in the MindWave transaction; the Company is not a broker-dealer, exchange or investment company, has not committed to a plan to sell any specific holding, and has not classified any digital asset as held for sale. Consistent with the presentation in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, digital assets are therefore classified as non-current under ASC 210-10-45-1. Sales made to fund operating requirements, including those contemplated by management’s plans described in the going-concern discussion in Note 2, are effected from time to time out of that non-current position and do not, individually or in the aggregate, represent a plan to dispose of the holdings. |